An international team of researchers has discovered a new anti-cancer protein.

The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver.

The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in Nature that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing.

In the last twenty years, the number of cases has almost doubled in Switzerland.

Hepatocellular carcinoma is usually diagnosed at a very late stage when the liver is already severely damaged and hence overall prognosis is poor.

Detection of the anti-cancer protein LHPP as a biomarker may allow clinicians to provide better treatment options.

Liver tumours develop from mutated cells that grow and proliferate uncontrollably.

Anti-cancer proteins, so-called tumour suppressors, prevent uncontrolled cell growth.

Tumour suppressors are often defective in cancer cells.

The researchers led by Prof. Michael N. Hall, Biozentrum of the University of Basel, have now discovered a new, so far unknown tumour suppressor, the protein LHPP.

In their study, they show that the loss of LHPP promotes tumour growth and reduces the chance of survival of cancer patients.

LHPP could potentially be used as a prognostic biomarker.

The researchers generated a mouse model for hepatocellular carcinoma by activating mTOR signalling specifically in the liver.

They analyzed a total of more than 4,000 proteins, comparing them in healthy and tumour tissue.

An enzyme emerged as the top favourite: the histidine phosphatase LHPP.

"It is striking that LHPP is present in healthy tissue and completely absent in tumour tissue," says first author Sravanth Hindupur. Re-introduction of the genetic information for LHPP by the researchers prevents the formation of tumours and maintains liver function.

"Similar to the mouse model, we also saw a striking decrease in LHPP levels in tumours of patients with liver cancer," says Hindupur.

Additionally, both disease severity and life expectancy correlate with LHPP levels.

With complete loss of the tumour suppressor, cancer patients die on average two years earlier.

LHPP is useful as a biomarker to classify tumours.

LHPP is a phosphatase that removes histidine-linked phosphate groups from proteins.

Like all amino acids, histidine is a basic component of proteins.

Histidine phosphorylation of proteins has been poorly investigated due to the lack of suitable tools.

"Tony Hunter, from the Salk Institute in the USA, has provided us with new tools to analyze histidine phosphorylation. We have now been able to visualize a whole new layer of complexity in tumour formation," says Hindupur.

Due to the absence of LHPP, global protein histidine phosphorylation is increased, which can lead to activation of several important functions and uncontrolled cell proliferation.

This absence promotes the growth of tumours via increasing histidine-phosphorylated proteins.

The tumour suppressor LHPP may also play a role in the development of other cancers.

Source: University of Basel